These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31530120)

  • 1. 45 GyRBE for group III orbital embryonal rhabdomyosarcoma.
    Indelicato DJ; Rotondo RL; Mailhot Vega RB; Uezono H; Bradfield S; Agarwal V; Hol ML; Bradley JA
    Acta Oncol; 2019 Oct; 58(10):1404-1409. PubMed ID: 31530120
    [No Abstract]   [Full Text] [Related]  

  • 2. Dose-Effect Analysis of Early Changes in Orbital Bone Morphology After Radiation Therapy for Rhabdomyosarcoma.
    Hol MLF; Indelicato DJ; Rotondo RL; Mailhot Vega RB; Uezono H; Lockney NA; Sandler E; Bradley JA
    Pract Radiat Oncol; 2020; 10(1):53-58. PubMed ID: 31629089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma.
    Buszek SM; Ludmir EB; Grosshans DR; McAleer MF; McGovern SL; Harrison DJ; Okcu MF; Chintagumpala MM; Mahajan A; Paulino AC
    Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):718-725. PubMed ID: 33516439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide.
    Casey DL; Wexler LH; Wolden SL
    Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1151-1157. PubMed ID: 30508617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Ermoian RP; Breneman J; Walterhouse DO; Chi YY; Meza J; Anderson J; Hawkins DS; Hayes-Jordan AA; Parham DM; Yock TI; Donaldson SS; Wolden SL
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28548706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of failure and toxicity profile following proton beam therapy for pediatric bladder and prostate rhabdomyosarcoma.
    Buszek SM; Ludmir EB; Grosshans DR; McAleer MF; McGovern SL; Harrison DJ; Okcu MF; Chintagumpala MM; Mahajan A; Paulino AC
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27952. PubMed ID: 31397065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of Failure in Pediatric Rhabdomyosarcoma After Proton Therapy.
    Vern-Gross TZ; Indelicato DJ; Bradley JA; Rotondo RL
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1070-1077. PubMed ID: 27742542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.
    Wolden SL; Lyden ER; Arndt CA; Hawkins DS; Anderson JR; Rodeberg DA; Morris CD; Donaldson SS
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1071-6. PubMed ID: 26581144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas.
    Chen C; Shu HK; Goldwein JW; Womer RB; Maity A
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1294-9. PubMed ID: 12654440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects.
    Childs SK; Kozak KR; Friedmann AM; Yeap BY; Adams J; MacDonald SM; Liebsch NJ; Tarbell NJ; Yock TI
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):635-42. PubMed ID: 21377294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes Following Proton Therapy for Group III Pelvic Rhabdomyosarcoma.
    Indelicato DJ; Rotondo RL; Krasin MJ; Mailhot Vega RB; Uezono H; Bradfield S; Agarwal V; Morris CG; Bradley JA
    Int J Radiat Oncol Biol Phys; 2020 Apr; 106(5):968-976. PubMed ID: 31987977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Raney RB; Walterhouse DO; Meza JL; Andrassy RJ; Breneman JC; Crist WM; Maurer HM; Meyer WH; Parham DM; Anderson JR
    J Clin Oncol; 2011 Apr; 29(10):1312-8. PubMed ID: 21357783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pencil Beam Scanning Proton Therapy for Pediatric Parameningeal Rhabdomyosarcomas: Clinical Outcome of Patients Treated at the Paul Scherrer Institute.
    Weber DC; Ares C; Albertini F; Frei-Welte M; Niggli FK; Schneider R; Lomax AJ
    Pediatr Blood Cancer; 2016 Oct; 63(10):1731-6. PubMed ID: 26701148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Orbital rhabdomyosarcoma: difficulties with European treatment protocol].
    Olivier Pascual N; Calvo JM; Abelairas Gómez JM
    Arch Soc Esp Oftalmol; 2005 Jun; 80(6):331-8. PubMed ID: 15986273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.
    Crist WM; Anderson JR; Meza JL; Fryer C; Raney RB; Ruymann FB; Breneman J; Qualman SJ; Wiener E; Wharam M; Lobe T; Webber B; Maurer HM; Donaldson SS
    J Clin Oncol; 2001 Jun; 19(12):3091-102. PubMed ID: 11408506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
    Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes and acute toxicities of proton therapy for pediatric atypical teratoid/rhabdoid tumor of the central nervous system.
    McGovern SL; Okcu MF; Munsell MF; Kumbalasseriyil N; Grosshans DR; McAleer MF; Chintagumpala M; Khatua S; Mahajan A
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1143-52. PubMed ID: 25311260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with completely resected nongenitourinary low-risk embryonal rhabdomyosarcoma are candidates for reduced duration low-intensity chemotherapy.
    Bisogno G; Fuchs J; Dasgupta R; Ferrari A; Haduong JH; Rogers T; Walterhouse DO; Coppadoro B; Xue W; Vokuhl C; Hawkins DS; Seitz G; Merks JHM; Sparber-Sauer M; Venkatramani R
    Cancer; 2022 Dec; 128(23):4150-4156. PubMed ID: 36250420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhabdomyosarcoma: the experience of the pediatric unit of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) (from January 1992 to January 2001).
    Abd El-Aal HH; Habib EE; Mishrif MM
    J Egypt Natl Canc Inst; 2006 Mar; 18(1):51-60. PubMed ID: 17237856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome and Patterns of Relapse in Childhood Parameningeal Rhabdomyosarcoma Treated With Proton Beam Therapy.
    Doyen J; Jazmati D; Geismar D; Frisch S; Schleithoff SS; Vermeren X; Scheer M; Blase C; Tippelt S; Timmermann B
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1043-1054. PubMed ID: 31419513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.